Zantac

Product brand

Zantac is a pharmaceutical brand historically associated with ranitidine and, after ranitidine's withdrawal, with famotidine-based acid-reduction products.

Last updated November 2, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Zantac is a gastrointestinal medicine brand best known for ranitidine, a histamine H2-receptor antagonist that reduces the production of gastric acid. Ranitidine was developed in the United Kingdom and commercialized by Glaxo, later part of GlaxoSmithKline. Introduced in the early 1980s, Zantac became one of the most widely used prescription treatments for peptic ulcers, gastroesophageal reflux disease, heartburn, and other acid-related disorders. It was sold in prescription and, in many markets, nonprescription forms, including tablets, capsules, syrups, and injectable formulations. The brand became a major pharmaceutical success because ranitidine combined effective acid suppression with a generally convenient dosing schedule. It was positioned as an alternative to earlier H2-receptor antagonists such as cimetidine and achieved extensive use in hospitals, primary care, and self-medication markets. Zantac became one of the earliest medicines to generate more than one billion dollars in annual sales, although figures varied by corporate reporting period and by whether global prescription and consumer sales were combined. Zantac's original identity changed substantially after regulators and manufacturers identified concerns about N-nitrosodimethylamine, or NDMA, in ranitidine products. In 2019, testing and recalls began in several markets. In April 2020, the United States Food and Drug Administration requested that all ranitidine products be withdrawn from the U.S. market because NDMA levels could increase during storage and under higher-temperature conditions. Manufacturers and regulators in other jurisdictions took comparable withdrawal or suspension actions. These events ended the original ranitidine-based Zantac business in many markets and generated extensive product-liability litigation. The Zantac name was subsequently used for a different active ingredient in the United States. Sanofi introduced Zantac 360° as an over-the-counter famotidine product for heartburn relief, distinguishing it from the withdrawn ranitidine formulation. The later brand therefore retains the Zantac name while representing a different medicine and a different regulatory history. Availability, formulation, ownership, and legal status vary by country, and the name should not be treated as evidence that current Zantac products contain ranitidine.

History

Zantac originated as the brand name for ranitidine, an H2-receptor antagonist developed in the United Kingdom by researchers working with Glaxo. Ranitidine was designed to suppress gastric-acid secretion by blocking histamine H2 receptors in the stomach. This mechanism made it useful for treating peptic ulcers and other acid-related conditions while addressing limitations associated with earlier medicines in the same class. Glaxo introduced Zantac in 1981. It was initially a prescription medicine, but it became a major treatment in gastroenterology and general medicine as clinical use expanded. The brand was marketed for conditions including duodenal and gastric ulcers, gastroesophageal reflux disease, and heartburn. Its commercial development included multiple dosage forms and, in various countries, a transition into nonprescription consumer use. Zantac's international success made it a landmark product for Glaxo and one of the best-known gastrointestinal medicine brands of the late twentieth century. The brand changed corporate context as Glaxo combined with other pharmaceutical businesses, ultimately becoming associated with GlaxoSmithKline. In different countries, licensing, manufacturing, distribution, and marketing arrangements varied, so the commercial owner of a particular Zantac product was not necessarily the same organization in every market. Generic ranitidine products also became widely available after patent and market exclusivity periods ended. The defining later event in Zantac's original history was the discovery of NDMA contamination concerns. In 2019, regulators and companies announced recalls, suspensions, and investigations after testing found NDMA in some ranitidine samples. Authorities examined both the amount initially present and the possibility that NDMA could form or increase during storage, particularly under elevated temperatures. In April 2020, the U.S. Food and Drug Administration requested removal of all ranitidine products from the U.S. market. Other national regulators adopted their own restrictions or withdrawals. These actions removed the historical ranitidine formulation from many major markets. The withdrawal led to product-liability claims against manufacturers, brand owners, distributors, and retailers. The litigation alleged that ranitidine users could have been exposed to NDMA and that companies had failed to adequately address the risk. The legal proceedings involved scientific disputes about causation and product testing, and outcomes differed across procedural stages and jurisdictions. The Zantac name later returned to the U.S. consumer market in a reformulated form. Sanofi introduced Zantac 360°, containing famotidine, another H2-receptor antagonist, rather than ranitidine. This relaunch preserved consumer recognition of the Zantac name but represented a new active ingredient and a different product identity. Consequently, references to Zantac must be interpreted by date and market: older references generally concern ranitidine, while current U.S. Zantac 360° references concern famotidine.

2022
Zantac 360° launches with famotidine
[4]Sanofi announces U.S. launch of Zantac 360°sanofi.com
Sanofi launched Zantac 360° in the United States as an over-the-counter famotidine product for heartburn relief.
2020
FDA requests removal of ranitidine products
[2]FDA Requests Removal of All Ranitidine Products (Zantac) from the Marketfda.gov
The FDA requested removal of all ranitidine products from the U.S. market because NDMA could increase during storage and under higher-temperature conditions.
2019
NDMA concern triggers recalls and investigations
[5]NDMA concern triggers recalls and investigationsfda.gov
Testing detected NDMA in some ranitidine products, prompting recalls, market suspensions, and regulatory investigations in multiple countries.
1981
Zantac is introduced
[1]Zantacen.wikipedia.org
Glaxo introduced Zantac as a prescription brand for ranitidine, an H2-receptor antagonist used to reduce gastric-acid secretion.

Products and positioning

Acid-reduction and heartburn-relief medicine; historically a prescription and over-the-counter ranitidine brand, and in the United States later repositioned as an over-the-counter famotidine brand.

H2-receptor antagonist · 1981
Zantac ranitidine
The original Zantac formulation contained ranitidine, which reduced gastric-acid secretion by blocking histamine H2 receptors. It was marketed in prescription and nonprescription forms, including tablets, capsules, oral liquids, and injectable products, depending on the country. Ranitidine Zantac products were withdrawn or suspended in many markets after NDMA contamination concerns.
Over-the-counter heartburn medicine · 2022
Zantac 360°
Zantac 360° is a later U.S. brand extension containing famotidine rather than ranitidine. It is positioned for relief and prevention of heartburn and uses the Zantac name while clearly representing a different active ingredient from the withdrawn historical product.

Controversies

2021
Virginia woman files Zantac cancer lawsuit
In a lawsuit reported in August 2021, Deborah Haskins sued the makers of Zantac, alleging that the drug caused her esophageal cancer and that its makers failed to warn consumers of the risks. The report notes that research had not explicitly linked Zantac to cancer. The filing is presented as a claim by the plaintiff; the article does not describe a court ruling or any finding of liability.
Source 1 Source 2
2020
FDA orders Zantac sales pulled from stores
In April 2020, the U.S. Food and Drug Administration ordered that Zantac be pulled from stores effective immediately. According to the report, U.S. officials cited a cancer-causing risk associated with the medication as the reason for the action. The order applied to store sales of the product, and the article describes the removal as taking effect right away. The report does not provide further details on the specific risk, the scope of the recall, or any subsequent regulatory steps.
Source
2019
NDMA contamination controversy
The discovery of NDMA in some ranitidine samples led to recalls, regulatory investigations, market withdrawals, and extensive public concern about the safety of Zantac and generic ranitidine products.
Source
2019
Zantac product-liability litigation
Patients filed lawsuits alleging that ranitidine products exposed them to NDMA and caused cancer or other injuries. The litigation involved multiple manufacturers, distributors, retailers, and brand-rights holders, with significant disputes over scientific evidence and causation.
Source
2019
GSK announces global Zantac recall
GlaxoSmithKline said it was recalling prescription-only Zantac medicines in all markets as a precaution after the U.S. Food and Drug Administration found unacceptable levels of a probable cancer-causing impurity in the drug. GSK said it was also suspending the release, distribution and supply of all dose forms of Zantac products.
Source
2019
Sanofi recalls Zantac in the United States and Canada
In October 2019, Sanofi announced a voluntary recall of Zantac from stores in the United States and Canada. The recall was announced while the company and regulators investigated NDMA detected in the drug. The source report describes the recall as covering the heartburn medication in both markets and links it to the investigation into the detected NDMA.
Source
2019
CVS suspends sales of Zantac and ranitidine products
CVS Pharmacy said it suspended sales of Zantac-brand and CVS Health-brand ranitidine products until further notice. The suspension followed an FDA alert that ranitidine products may contain a possible human carcinogen. According to the source, the products had not been recalled, and the FDA was not recommending that patients stop taking them.
Source

2022
Reformulation under the Zantac 360° nameProduct launch
Background
Following the withdrawal of ranitidine products, the Zantac name had to be separated from the original active ingredient.
Action taken
Sanofi launched Zantac 360° as an over-the-counter famotidine product in the United States.
Aftermath
The brand returned to the U.S. consumer market with a different H2-receptor antagonist and a distinct product identity.
Source
2020
Withdrawal of ranitidine from the U.S. marketOther
Background
Regulators concluded that NDMA levels in ranitidine could increase over time and under higher-temperature storage conditions.
Action taken
The FDA requested that manufacturers withdraw all prescription and over-the-counter ranitidine products from the United States.
Aftermath
The original ranitidine-based Zantac business ended in the United States, while other countries adopted their own restrictions and withdrawal measures.
Source

Recent events

2022
Sanofi launches Zantac 360° with famotidine[4]Sanofi announces U.S. launch of Zantac 360°sanofi.com
Product launch · Product generation
Sanofi launched Zantac 360° in the United States as an over-the-counter heartburn product containing famotidine rather than ranitidine.

Sources17 sources

Cite this profile: Cite the canonical profile. /brand-wiki/zantac · Editorial policy · How profiles are compiled